1887

Journal of General Virology header logo

Volume 77, Issue 4

Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope Free

Abstract

Antibodies elicited during natural infection of domestic cats by the feline immunodeficiency virus (FIV) recognize continuous epitopes in nine domains of the virus envelope glycoproteins. Whereas antibodies directed against the V3 envelope region can neutralize laboratory-adapted virus, neutralization of FIV has been shown to depend upon cellular substrate, and virus adaptation to laboratory cell lines may alter sensitivity to neutralizing antibodies. We therefore undertook a systematic analysis of the continuous B cell epitopes of the envelope of a primary FIV isolate, Wo. The capacity of feline antisera elicited against nine envelope domains to neutralize primary and laboratory-adapted virus was evaluated in feline peripheral blood mononuclear cells (PBMC). The laboratory-adapted strain Petaluma was used to compare neutralization in PBMC and Crandell feline kidney cells (CrFK). Antibodies specific for the V3 region neutralized both primary and laboratory-adapted virus whether residual infectivity was measured in CrFK or in feline PBMC. However, a large discrepancy in the efficiency of neutralization was observed in these models of infection, perhaps reflecting diversity in the interaction between virus and different cellular targets. We also examined the accessibility of epitopes on the functional oligomeric envelope complex of FIV. Most of the epitopes were poorly exposed on native envelope glycoproteins at the surface of live infected cells. The most accessible domain was the only domain sensitive to neutralizing antibodies. These results suggest that inaccessibility on oligomeric envelope glycoproteins may frequently underlie the insensitivity of diverse lentivirus B cell epitopes to neutralization.

  • Received:
  • Accepted:
  • Published Online:
© Journal of General Virology 1996
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-4-759
1996-04-01
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/4/JV0770040759.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-4-759&mimeType=html&fmt=ahah

References

  1. Avraméas A., Strosberg A. D., Moraillon A., Sonigo P., Pancino G. 1993; Serological diagnosis of feline immunodeficiency virus (FIV) infection based on synthetic peptides from Env glycoproteins. Research in Virology 144:209–218
     [Google Scholar]
  2. Baldinotti F., Matteucci D., Mazzetti P., Giannelli C., Bandecchi P., Tozzini F., Bendinelli M. 1994; Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. Journal of Virology 68:4572–4579
     [Google Scholar]
  3. Broder C. C., Earl P. L., Long D., Abedon S. T., Moss B., Doms R. W. 1994; Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomerspecific and -sensitive monoclonal antibodies. Proceedings of the National Academy of Sciences, USA 91:11699–11703
     [Google Scholar]
  4. De Ronde A., Stam J. G., Boers P., Langeduk H., Meloen R., Hesselink W., Lian C. E., Keldermans J. M., Van Vliet A., Verschoor E. J., Horzinek M. C., Egberink H. F. 1994; Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 198:257–264
     [Google Scholar]
  5. Dimmock N. J. 1993; Neutralization of animal viruses. Current Topics in Microbiology and Immunology 183:1–149
     [Google Scholar]
  6. Earl P. L., Broder C. C., Long D., Lee S. A., Peterson J., Chakrabarti S., Doms R. W., Moss B. 1994; Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. Journal of Virology 68:3015–3026
     [Google Scholar]
  7. Fevereiro M., Roneker C., Laues A., Tavares L., de Noronha F. 1991; Characterization of two monoclonal antibodies against feline immunodeficiency virus gag gene products and their application in an assay to evaluate neutralizing antibody activity. Journal of General Virology 72:617–622
     [Google Scholar]
  8. Fontenot J. D., Hoover E. A., Elder J. H., Montelaro R. C. 1992; Evaluation of feline immunodeficiency virus and feline leukemia virus transmembrane peptides for serological analysis. Journal of Clinical Microbiology 30:1885–1890
     [Google Scholar]
  9. Fultz P. N., Nara P., Barre-Sinoussi F., Chaput A., Greenburg M. L., Muchmore E., Kieny M.-P., Girard M. 1992; Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cell. Science 256:1687–1689
     [Google Scholar]
  10. Girard M., Kieny M.-P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E., Ronco J., Kaczorek M., Gomard E., Gluckman J.-C., Fultz P. N. 1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 88:542–546
     [Google Scholar]
  11. Ho D. D., McKeating J. A., Li X. L., Moudgil T., Daar E. S., Sun N.-C., Robinson J. E. 1991; Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type-1 neutralization identified by a human monoclonal antibody. Journal of Virology 65:489–493
     [Google Scholar]
  12. Hohdatsu T., Pu R., Torres B. A., Trujillo S., Gardner M. B., Yamamoto J. K. 1993; Passive antibody protection of cats against feline immunodeficiency virus infection. Journal of Virology 67:2344–2348
     [Google Scholar]
  13. Homsy J., Tateno M., Levy J. A. 1988; Antibody-dependent enhancement of HIV infection. Lancet i:1285–1286
     [Google Scholar]
  14. Homsy J., Meyer M., Tateno M., Clarkson S., Levy J. A. 1989; The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244:1357–1360
     [Google Scholar]
  15. Hosie M. G., Osborne R., Reid G., Neil J. C., Jarrett O. 1992; Enhancement after feline immunodeficiency virus vaccination. Veterinary Immunology and Immunopathology 35:191–197
     [Google Scholar]
  16. Hurtrel M., Ganiere J.-P., Guelfi J.-F., Chakrabarti L., Maire M.-A., Gray F., Montagnier L., Hurtrel B. 1992; Comparison of early and late feline immunodeficiency virus encephalopathies. AIDS 6:399–406
     [Google Scholar]
  17. Huynh T. V., Young R. A., Davis R. W. 1985 Constructing and Screening cDNA Libraries in λgt10 and λgt11 pp 49–78 Oxford: IRL Press;
     [Google Scholar]
  18. Hwang S. S., Boyle T. J., Lyerly H. K., Cullen B. R. 1991; Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71–73
     [Google Scholar]
  19. Lombardi S., Garzelli C., La Rosa C., Zaccaro L., Specter S., Malvaldi G., Tozzini F., Esposito F., Bendinelli M. 1993; Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. Journal of Virology 67:4742–4749
     [Google Scholar]
  20. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., Da Prato L., Bandecchi P., Tozzini F., Bendinelli M. 1994; A neutralizing antibodyinducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. Journal of Virology 68:8374–8379
     [Google Scholar]
  21. Lombardi S., Massi C., Tozzini F., Zaccaro L., Bazzichi A., Bandecchi P., La Rosa C., Bendinelli M., Garzelli C. 1995; Epitope mapping of the V3 domain of feline immunodeficiency virus envelope glycoprotein by monoclonal antibodies. Journal of General Virology 16:1893–1899
     [Google Scholar]
  22. Mascola J. R., Mathieson B. J., Zack P. M., Walker M. C., Halstead S. B., Burke D. S. 1993; Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Research and Human Retroviruses 9:1175–1184
     [Google Scholar]
  23. Moore J. P., Ho D. D. 1992; Antibodies to discontinuous or confonnationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. Journal of Virology 61:863–875
     [Google Scholar]
  24. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III, Burton D. R., Ho D. D. 1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology 69:101–109
     [Google Scholar]
  25. Moraillon A., Barre-Sinoussi F., Parodi A., Moraillon R., Dauguet C. 1992; In vitro properties and experimental pathogenic effect of three feline immunodeficiency viruses (FIV) isolated from cats with terminal disease. Veterinary Microbiology 31:41–54
     [Google Scholar]
  26. Nara P. L., Garrity R. R., Goudsmit J. 1991; Neutralization of HIV-1: a paradox of humoral proportions. FASEB Journal 5:2437–2455
     [Google Scholar]
  27. Norrby E., Matthews T. 1993; B-cell antigenic sites in the envelope proteins of primate lentiviruses and their role in vaccine development. AIDS 1 supplementum 1:27–33
     [Google Scholar]
  28. Osborne R., Rigby M., Siebelink K., Neil J. C., Jarrett O. 1994; Virus neutralization reveals antigenic variation among feline immunodeficiency virus isolates. Journal of General Virology 75:3641–3645
     [Google Scholar]
  29. Pancino G., Chappey C., Saurin W., Sonigo P. 1993; B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins. Journal of Virology 61:664–672
     [Google Scholar]
  30. Pancino G., Camoin L., Sonigo P. 1995a; Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein. Journal of Virology 69:2110–2118
     [Google Scholar]
  31. Pancino G., Castelot S., Sonigo P. 1995b; Differences in feline immunodeficiency virus (FIV) host cell range correlate with envelope fusogenic properties. Virology 206:796–806
     [Google Scholar]
  32. Pu R., Okada S., Little E. R., Xu B., Stoffs W. V., Yamamoto J. K. 1995; Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodies. AIDS 9:235–242
     [Google Scholar]
  33. Rigby M. A., Holmes E. C., Pistello M., Mackay A., Brown A. J. L., Neil J. C. 1993; Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. Journal of General Virology 74:425–436
     [Google Scholar]
  34. Robinson W. E., Montbfiori D. C., Mitchell W. M. 1988; Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet i:790–794
     [Google Scholar]
  35. Robinson W. E., Montbfiori D. C., Mitchell W. M. 1990; Complement-mediated antibody-dependent enhancement of HIV–1 infection requires CD4 and complement receptors. Virology 175:600–604
     [Google Scholar]
  36. Sattentau Q. J., Moore J. P. 1995; Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. Journal of Experimental Medicine 182:185–196
     [Google Scholar]
  37. Siebelink K. H. J., Tijhaar E., Huisman R. C., Huisman W., De Ronde A., Darby I. H., Francis M. J., Rimmelzwaan G. F., Osterhaus A. D. M. E. 1995a; Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. Journal of Virology 69:3704–3711
     [Google Scholar]
  38. Siebelink K. H. J., Huisman W., Karlas J. A., Rimmelzwaan G. F., Bosch M. L., Osterhaus A. D. M. E. 1995b; Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein. Journal of Virology 69:5124–5127
     [Google Scholar]
  39. Sodora D. L., Shpaer E. G., Kitchell B., Dow S. W., Hoover E. A., Mullins J. I. 1994; Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. Journal of Virology 68:2230–2238
     [Google Scholar]
  40. Stanley K. K. 1988; Producing antibodies of predetermined specificity from E. coli hybrid proteins. Methods in Molecular Biology 4:343–349
     [Google Scholar]
  41. Stanley K. K., Luzio J. P. 1984; Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins. EMBO Journal 3:1429–1433
     [Google Scholar]
  42. Sullivan N., Sun Y., Li J., Hofman W., Sodroski J. 1995; Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology 69:4413–4422
     [Google Scholar]
  43. Takeda A., Tuazon C. U., Ennis F. A. 1988; Antibody-enhanced infection by HIV–1 via Fc receptor-mediated entry. Science 242:580–583
     [Google Scholar]
  44. Talbott R. L., Sparger E. E., Lovelace K. M., Fitch W. M., Pedersen N. C., Luciw P. A., Elder J. H. 1989; Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 86:5743–5747
     [Google Scholar]
  45. Tozzini F., Matteucci D., Bandecchi P., Baldinotti F., Siebelink K., Osterhaus A., Bendinelli M. 1993; Neutralizing antibodies in cats infected with feline immunodeficiency virus. Journal of Clinical Microbiology 31:1626–1629
     [Google Scholar]
  46. Verschoor E. J., Boven L. A., Blaak H., Van Vliet A. L. W. 1995; A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells. Journal of Virology 69:4752–4757
     [Google Scholar]
  47. Vogel T., Kurth R., Norley S. 1994; The majority of neutralizing Abs in IIIV-l-infected patients recognize linear V3 loop sequences. Journal of Immunology 153:1895–1904
     [Google Scholar]
  48. Westervelt P., Gendelman H. E., Ratner L. 1991; Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proceedings of the National Academy of Sciences, USA 88:3097–3101
     [Google Scholar]
  49. Wrin T., Loh T. P., Vennari J. C., Schuitemaker H., Nunberg J. H. 1995; Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. Journal of Virology 69:39–48
     [Google Scholar]
  50. Yamamoto J. K., Ackley C. D., Zochlinski H., Louie H., Pembroke E., Torten M., Hansen H., Munn R., Okuda T. 1991; Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology 32:361–375
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-4-759
Loading
Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope
J. Gen. Virol. 77, 759 (1996); https://doi.org/10.1099/0022-1317-77-4-759
/content/journal/jgv/10.1099/0022-1317-77-4-759
/content/journal/jgv/10.1099/0022-1317-77-4-759
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error